Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

724 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Musette P, Joly P; French Study Group on Autoimmune Bullous Diseases. Chen DM, et al. Among authors: delaporte e. Br J Dermatol. 2020 May;182(5):1111-1119. doi: 10.1111/bjd.18482. Epub 2019 Nov 28. Br J Dermatol. 2020. PMID: 31487383 Free PMC article. Clinical Trial.
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P; French study group on autoimmune bullous skin diseases. Joly P, et al. Among authors: delaporte e. Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22. Lancet. 2017. PMID: 28342637 Clinical Trial.
Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D'Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; French Study Group on Autoimmune Bullous Skin Diseases; Autoimmune Bullous Skin Disease Task Force of the European Academy of Dermatology and Venereology. Hébert V, et al. Among authors: delaporte e. J Invest Dermatol. 2019 Jan;139(1):31-37. doi: 10.1016/j.jid.2018.04.042. Epub 2018 Oct 6. J Invest Dermatol. 2019. PMID: 30301637 Free article. Review.
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
Mignard C, Maho-Vaillant M, Golinski ML, Balayé P, Prost-Squarcioni C, Houivet E, Calbo SB, Labeille B, Picard-Dahan C, Konstantinou MP, Chaby G, Richard MA, Bouaziz JD, Duvert-Lehembre S, Delaporte E, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bédane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Joly P, Hébert V; French Study Group on Autoimmune Bullous Skin Diseases. Mignard C, et al. Among authors: delaporte e. JAMA Dermatol. 2020 May 1;156(5):545-552. doi: 10.1001/jamadermatol.2020.0290. JAMA Dermatol. 2020. PMID: 32186656 Free PMC article. Clinical Trial.
A single cycle of rituximab for the treatment of severe pemphigus.
Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P. Joly P, et al. Among authors: delaporte e. N Engl J Med. 2007 Aug 9;357(6):545-52. doi: 10.1056/NEJMoa067752. N Engl J Med. 2007. PMID: 17687130 Free article. Clinical Trial.
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.
Joly P, Roujeau JC, Benichou J, Delaporte E, D'Incan M, Dreno B, Bedane C, Sparsa A, Gorin I, Picard C, Tancrede-Bohin E, Sassolas B, Lok C, Guillaume JC, Doutre MS, Richard MA, Caux F, Prost C, Plantin P, Chosidow O, Pauwels C, Maillard H, Saiag P, Descamps V, Chevrant-Breton J, Dereure O, Hellot MF, Esteve E, Bernard P. Joly P, et al. Among authors: delaporte e. J Invest Dermatol. 2009 Jul;129(7):1681-7. doi: 10.1038/jid.2008.412. Epub 2009 Jan 29. J Invest Dermatol. 2009. PMID: 19177141 Free article. Clinical Trial.
Prognostic factors of paraneoplastic pemphigus.
Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, Carsuzaa F, Chaumentin G, Chevrant-Breton J, Chosidow O, Crickx B, D'incan M, Dandurand M, Debarbieux S, Delaporte E, Dereure O, Doutre MS, Guillet G, Jullien D, Kupfer I, Lacour JP, Leonard F, Lok C, Machet L, Martin L, Paul C, Pignon JM, Robert C, Thomas L, Weiller PJ, Ferranti V, Gilbert D, Courville P, Houivet E, Benichou J, Joly P. Leger S, et al. Among authors: delaporte e. Arch Dermatol. 2012 Oct;148(10):1165-72. doi: 10.1001/archdermatol.2012.1830. Arch Dermatol. 2012. PMID: 22801794
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
Colliou N, Picard D, Caillot F, Calbo S, Le Corre S, Lim A, Lemercier B, Le Mauff B, Maho-Vaillant M, Jacquot S, Bedane C, Bernard P, Caux F, Prost C, Delaporte E, Doutre MS, Dreno B, Franck N, Ingen-Housz-Oro S, Chosidow O, Pauwels C, Picard C, Roujeau JC, Sigal M, Tancrede-Bohin E, Templier I, Eming R, Hertl M, D'Incan M, Joly P, Musette P. Colliou N, et al. Among authors: delaporte e. Sci Transl Med. 2013 Mar 6;5(175):175ra30. doi: 10.1126/scitranslmed.3005166. Sci Transl Med. 2013. PMID: 23467561
Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases.
Heidelberger V, Ingen-Housz-Oro S, Marquet A, Mahevas M, Bessis D, Bouillet L, Caux F, Chapelon-Abric C, Debarbieux S, Delaporte E, Duval-Modeste AB, Fain O, Joly P, Marchand-Adam S, Monfort JB, Noël N, Passeron T, Ruivard M, Sarrot-Reynauld F, Verrot D, Bouvry D, Fardet L, Chosidow O, Sève P, Valeyre D. Heidelberger V, et al. Among authors: delaporte e. JAMA Dermatol. 2017 Jul 1;153(7):681-685. doi: 10.1001/jamadermatol.2017.1162. JAMA Dermatol. 2017. PMID: 28564695 Free PMC article.
Incidence and Mortality of Pemphigus in France.
Jelti L, Cordel N, Gillibert A, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D'incan M, Verneuil L, Litrowski N, Joly P; French Study Group on Autoimmune Blistering Diseases. Jelti L, et al. Among authors: delaporte e. J Invest Dermatol. 2019 Feb;139(2):469-473. doi: 10.1016/j.jid.2018.07.042. Epub 2018 Sep 17. J Invest Dermatol. 2019. PMID: 30236611 Free article. No abstract available.
724 results